Other News To Note
Cell Therapeutics Inc., of Seattle, said its board approved certain amendments to the firm's existing shareholder rights plan to decrease the exercise price of the preferred stock purchase rights from $14 to $8 and to extend the final expiration date from the close of business on the third anniversary of Jan. 7, 2010, to the close of business on Dec. 3, 2015.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.